For anyone in Mol looking to source CJC-1295, the foundational reality is that this compound is available only through an online research supply market. The key implication for Mol researchers: sourcing CJC-1295 hinges on vendor quality evaluation, not geography — and the evaluation methodology is the same regardless of where you are. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. This guide gives Mol researchers the framework to assess vendor quality rigorously and source verified-quality CJC-1295 with confidence.
CJC-1295 Mechanisms Explained
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Mol studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
CJC-1295 Purchasing Guide
Vetting CJC-1295 vendors requires starting from the COA: request the batch-specific certificate before placing an order, not after. When reviewing a CJC-1295 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec establishes identity, and endotoxin levels are within acceptable research limits. For Mol researchers evaluating unfamiliar vendors: a modest first purchase to test the product before placing larger orders is the accepted approach among experienced researchers. For Mol researchers making a first CJC-1295 purchase: verify the vendor against this framework, start with a modest quantity, and verify batch traceability on arrival before use.
Order CJC-1295 — ships to Mol
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the known safety profile is based on research literature rather than clinical trials. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. The main safety concern arising from sourcing in CJC-1295 research is endotoxin contamination from poor sourcing — a confirmed endotoxin test result in the lot-matched COA is the direct mitigation for this hazard. The research literature on CJC-1295 should be read critically before planning any study — study designs, dosing ranges, and outcome measures vary significantly and results do not always generalise across models.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
